Cytokinetics (CYTK) said Friday that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China to treat obstructive and non-obstructive hypertrophic cardiomyopathy.
The company said Corxel Pharmaceuticals acquired the rights to aficamten in Greater China from Cytokinetics in 2020. Sanofi is acquiring the rights from Corxel for an undisclosed amount.
Cytokinetics will be eligible to receive up to $150 million in development and commercial milestone payments from Sanofi, as well as royalties in the low-to-high teens on future sales in the region, the company said.
Cytokinetics is also eligible for further undisclosed payments tied to the agreement between Sanofi and Corxel, it said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。